BioTrack Capital

BioTrack Capital is a Shanghai-based venture firm specializing in early-stage biopharma and medtech innovation within the Chinese life sciences ecosystem, with a focus on biotech and life sciences tools at Series A and Series B. The firm operates as a healthcare specialist rather than a generalist tech investor, and its sub-vertical mix suggests appetite for novel modalities, platform technologies, and the tooling layer that supports broader life sciences industrialization in China. Limited public information about named partners and specific recent portfolio additions is available in English-language sources, so founders should expect to validate details through direct outreach and Chinese-language coverage.

Check sizes range from 5 million to 25 million dollars at Series A and Series B, sized to support meaningful clinical or commercial milestones in life sciences companies where capital intensity is high. Geography centers on China with Shanghai as the hub, and the firm is positioned to support founders navigating the Chinese regulatory, clinical trial, and manufacturing environment. Companies operating purely outside the Chinese life sciences corridor will not align with the thesis.

The approach is suited to scientist-founders and operators with specific China-market ambitions who want investors fluent in NMPA pathways, local CRO and CDMO networks, and the practicalities of building biotech or medtech in the Chinese ecosystem. Those expecting a Western-style early-stage venture process should calibrate for differences in pace, syndication norms, and reporting expectations. Initial conversations should focus on the company’s clinical strategy, China-market plan, and what specific operational support BioTrack offers beyond capital, particularly around regulatory navigation and downstream syndicate construction.